We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Harvard Bioengineers’ Biomaterial-Based Cancer Immunotherapies to be Developed by Novartis

News   Mar 23, 2018 | Original story from The Wyss Institute

 
Harvard Bioengineers’ Biomaterial-Based Cancer Immunotherapies to be Developed by Novartis

Made of the polymer that’s used in biodegradable sutures, this aspirin-sized device is designed to deliver immunotherapy agents that activate the immune system against tumors. Image courtesy of the Wyss Institute at Harvard University

 
 
 

RELATED ARTICLES

Previously Undiscovered Immune Cell Population Affects Learning and Memory

News

A new study has suggested that not only are there immune cell populations hiding undiscovered in the body, but they might have impacts far beyond protection from intruding microorganisms.

READ MORE

Imaging Tumor Stiffness To Enhance Breast and Pancreatic Cancer Treatments

News

Using a non-invasive imaging technique that measures the stiffness of tissues gives vital new information about cancer architecture and could aid the delivery of treatment to challenging tumors.

READ MORE

Improving Nature’s Own Ability To Kill Dangerous Bacteria

News

The ramifications of bacteria's ability to become resistant to antibiotics can be seen in hospitals, public places, our food supply, and our water. Now, researchers have demonstrated how we could improve upon the ability of nature's exquisitely selective collection of antimicrobial enzymes to attack bacteria in a way that's much less likely to cause bacterial resistance.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE